Moreover, HES1 shRNA administration abrogated the ECM up-regulation and ameliorated the functional defects (Figure 5 and 6), thereby implicating a novel and effective therapeutic modality to the POAG that warrants further development. The gene discussed is HES1; the disease is open-angle glaucoma.